Due to their long-standing relationship, Checkmate’s Chief Medical Officer has again partnered with The Chase Group as he builds his clinical team. Founded in 2015 to demonstrate the power and potential of activating the immune system to improve cancer care and patient outcomes, Checkmate Pharmaceuticals is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies and new treatment options for patients and healthcare providers. The Chase Group is honored to work with Checkmate and eager to locate a medical oncologist for this newly created leadership opportunity. This first critical hire will fill a high-profile, lead development role that will report directly to the CMO. Despite the impact of COVID-19, we remain focused on keeping a long-term perspective in this short-term uncertainty. The work we all do within life sciences is critical to our future and though working remotely, we continue to drive science forward. For more information, please contact email@example.com.